REFERENCES1. Grady WM, Carethers JM (2008) Ge<strong>no</strong>mic <strong>and</strong> Epi<strong>genetic</strong> Instability <strong>in</strong> ColorectalCancer Pathogenesis. Gastroenterology 135(4): 1079-10992. Issa JP (2004) CpG isl<strong>and</strong> methylator phe<strong>no</strong>type <strong>in</strong> cancer. Nat Rev Cancer 4(12):988-9933. Kunkel TA (1993) Nucleotide repeats. Slippery DNA <strong>and</strong> diseases. Nature365(6443): 207-2084. Li YC, Korol AB, Fahima T, Beiles A, Nevo E (2002) Microsatellites: ge<strong>no</strong>micdistribution, putative functions <strong>and</strong> mutational mechanisms: a review. Mol Ecol11(12): 2453-24655. Shibata D, Pe<strong>in</strong>ado MA, Io<strong>no</strong>v Y, Malkhosyan S, Perucho M (1994) Ge<strong>no</strong>mic<strong>in</strong>stability <strong>in</strong> repeated sequences is an early somatic event <strong>in</strong> colorectaltumorigenesis that persists after transformation. Nat Genet 6(3): 273-2816. Bol<strong>and</strong> CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW,Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) ANational Cancer Institute Workshop on Microsatellite Instability for cancerdetection <strong>and</strong> familial predisposition: development of <strong>in</strong>ternational criteria forthe determ<strong>in</strong>ation of microsatellite <strong>in</strong>stability <strong>in</strong> colorectal cancer. Cancer Res58(22): 5248-52577. Kuismanen SA, Holmberg MT, Salovaara R, de la CA, Peltomäki P (2000) Genetic<strong>and</strong> epi<strong>genetic</strong> modification of MLH1 accounts for a major share ofmicrosatellite-unstable colorectal cancers. Am J Pathol 156(5): 1773-17798. Duval A, Roll<strong>and</strong> S, Compo<strong>in</strong>t A, Tubacher E, Iacopetta B, Thomas G, Hamel<strong>in</strong> R(2001) Evolution of <strong>in</strong>stability at cod<strong>in</strong>g <strong>and</strong> <strong>no</strong>n-cod<strong>in</strong>g repeat sequences <strong>in</strong>human MSI-H colorectal cancers. Hum Mol Genet 10(5): 513-5189. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite<strong>in</strong>stability <strong>and</strong> colorectal cancer prog<strong>no</strong>sis. J Cl<strong>in</strong> Oncol 23(3): 609-61810. Røyrvik EC, Ahlquist T, Rognes T, Lothe RA (2007) Slip slid<strong>in</strong>' away: aduodecennial review of targeted genes <strong>in</strong> mismatch repair deficient colorectalcancer. Crit Rev Oncog 13(3): 229-25711. Mel<strong>in</strong>g GI, Lothe RA, Børresen AL, Hauge S, Graue C, Clausen OP, Rognum TO(1991) Genetic <strong>alterations</strong> with<strong>in</strong> the ret<strong>in</strong>oblastoma locus <strong>in</strong> colorectalcarc<strong>in</strong>omas. Relation to DNA ploidy pattern studied by flow cytometricanalysis. Br J Cancer 64(3): 475-48024
12. Duval A, Reperant M, Hamel<strong>in</strong> R (2002) Comparative analysis of mutationfrequency of cod<strong>in</strong>g <strong>and</strong> <strong>no</strong>n cod<strong>in</strong>g short mo<strong>no</strong>nucleotide repeats <strong>in</strong> mismatchrepair deficient colorectal cancers. Oncogene 21(52): 8062-806613. Hanahan D, We<strong>in</strong>berg RA (2000) The hallmarks of cancer. Cell 100(1): 57-7014. Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G, Bork P, DoeberitzMK, Gebert JF (2003) Pathogenesis of DNA repair-deficient cancers: a statisticalmeta-analysis of putative Real Common Target genes. Oncogene 22(15): 2226-223515. Duffy MJ, van DA, Haglund C, Hansson L, Hol<strong>in</strong>ski-Feder E, Klapdor R, Lamerz R,Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers <strong>in</strong> colorectal cancer:European Group on Tumour Markers (EGTM) guidel<strong>in</strong>es for cl<strong>in</strong>ical use. Eur JCancer 43(9): 1348-136016. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, SomerfieldMR, Hayes DF, Bast RC, Jr. (2006) ASCO 2006 update of recommendations for theuse of tumor markers <strong>in</strong> gastro<strong>in</strong>test<strong>in</strong>al cancer. J Cl<strong>in</strong> Oncol 24(33): 5313-532717. Fern<strong>and</strong>ez-Peralta AM, Nejda N, Oliart S, Med<strong>in</strong>a V, Azcoita MM, Gonzalez-AguileraJJ (2005) Significance of mutations <strong>in</strong> TGFBR2 <strong>and</strong> BAX <strong>in</strong> neoplasticprogression <strong>and</strong> patient outcome <strong>in</strong> sporadic colorectal tumors with highfrequencymicrosatellite <strong>in</strong>stability. Cancer Genet Cytogenet 157(1): 18-2418. Io<strong>no</strong>v Y, Yamamoto H, Krajewski S, Reed JC, Perucho M (2000) Mutational<strong>in</strong>activation of the proapoptotic gene BAX confers selective advantage dur<strong>in</strong>gtumor clonal evolution. Proc Natl Acad Sci U S A 97(20): 10872-1087719. Jung B, Smith EJ, Doctolero RT, Gervaz P, Alonso JC, Miyai K, Keku T, S<strong>and</strong>ler RS,Carethers JM (2006) Influence of target gene mutations on survival, stage <strong>and</strong>histology <strong>in</strong> sporadic microsatellite unstable colon cancers. Int J Cancer 118(10):2509-251320. Watanabe T, Wu TT, Catala<strong>no</strong> PJ, Ueki T, Satria<strong>no</strong> R, Haller DG, Benson AB, III,Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapyfor colon cancer. N Engl J Med 344(16): 1196-120621. Samowitz WS, Curt<strong>in</strong> K, Neuhausen S, Schaffer D, Slattery ML (2002) Prog<strong>no</strong>sticimplications of BAX <strong>and</strong> TGFBRII mutations <strong>in</strong> colon cancers withmicrosatellite <strong>in</strong>stability. Genes Chromosomes Cancer 35(4): 368-37122. Lewis KA, Bakkum-Gamez J, Loewen R, French AJ, Thibodeau SN, Cliby WA (2007)Mutations <strong>in</strong> the ataxia telangiectasia <strong>and</strong> rad3-related-checkpo<strong>in</strong>t k<strong>in</strong>ase 1DNA damage response axis <strong>in</strong> colon cancers. Genes Chromosomes Cancer 46(12):1061-106823. Nehls O, Okech T, Hsieh CJ, Enz<strong>in</strong>ger T, Sarbia M, Borchard F, Gruenagel HH, GacoV, Hass HG, Arkenau HT, Hartmann JT, Porschen R, Gregor M, Klump B (2007)25
- Page 1 and 2:
Novel genetic and epigenetic altera
- Page 3 and 4:
TABLE OF CONTENTSACKNOWLEDGEMENTS .
- Page 5 and 6:
ACKNOWLEDGEMENTSThe present work ha
- Page 7 and 8:
Prefacetechnology[3]. This new tech
- Page 10 and 11:
SummaryThe subgroup of carcinomas w
- Page 12 and 13:
Introduction“Epigenetic inheritan
- Page 14 and 15:
Introductionamino acid change it is
- Page 16 and 17:
Introductionmethylation during embr
- Page 18 and 19:
IntroductionDNA is most of the time
- Page 20 and 21:
IntroductionFigure 5. DNA methylati
- Page 22 and 23:
IntroductionFigure 6. Incidence rat
- Page 24 and 25:
IntroductionFigure 8. Tumor staging
- Page 26 and 27:
Introductioninasmuch as 80% of colo
- Page 28 and 29:
IntroductionInstabilities involved
- Page 30 and 31:
Introductionthere seems to be a fid
- Page 32 and 33:
Introductionsevere alterations are
- Page 34 and 35:
Introductionpopulation-wide screeni
- Page 36 and 37:
IntroductionFigure 12. Present and
- Page 38 and 39:
RESULTS IN BRIEFPaper Ia. “DNA hy
- Page 40 and 41:
Results in Briefinstability, and se
- Page 42 and 43:
Results in BriefUnivariate survival
- Page 44 and 45:
Discussionseveral factors, and full
- Page 46 and 47:
Discussionlow threshold, we increas
- Page 48 and 49:
DiscussionIt may seem like unnecess
- Page 50 and 51:
Discussionthan 96% DHPLC do not sta
- Page 52 and 53:
DiscussionFigure 13. Mutation detec
- Page 54 and 55:
DiscussionClinical impact of molecu
- Page 56 and 57:
Discussionmarkers with a very high
- Page 58 and 59:
Discussionchromosomes in metaphase[
- Page 60 and 61:
DiscussionThese examples underline
- Page 62 and 63:
Discussiongenes. One is based on mu
- Page 64 and 65:
CONCLUSIONSWe have identified novel
- Page 66 and 67:
Future PerspectivesMolecular risk a
- Page 68 and 69:
REFERENCES1. Breasted J (1930) The
- Page 70 and 71:
References29. Deng G, Chen A, Pong
- Page 72 and 73:
References57. Al-Sukhni W, Aronson
- Page 74 and 75:
References84. Kunkel TA (1993) Nucl
- Page 76 and 77:
ReferencesLeggett B, Levine J, Kim
- Page 78 and 79:
References133. Lind GE, Thorstensen
- Page 80 and 81:
References156. Meling GI, Lothe RA,
- Page 82 and 83:
ReferencesT, Song X, Day RH, Sledzi
- Page 84 and 85:
References196. Honda S, Haruta M, S
- Page 86 and 87:
ORIGINAL ARTICLESAPPENDIXAppendix I
- Page 89 and 90:
GASTROENTEROLOGY 2007;132:1631-1639
- Page 91:
Paper IbGuro E Lind, Terje Ahlquist
- Page 94 and 95:
Journal of Translational Medicine 2
- Page 96 and 97:
Journal of Translational Medicine 2
- Page 98 and 99:
Journal of Translational Medicine 2
- Page 100 and 101:
Journal of Translational Medicine 2
- Page 102 and 103:
Journal of Translational Medicine 2
- Page 105: Paper IITerje Ahlquist, Guro E Lind
- Page 108 and 109: BackgroundMost cases of colorectal
- Page 110 and 111: ADAMTS1 CDKN2A CRABP1 HOXA9 MAL MGM
- Page 112 and 113: pseudogene, leading to a high rate
- Page 114 and 115: strands. Proc Natl Acad Sci U S A 1
- Page 116 and 117: concomitant absence of transcript a
- Page 119 and 120: Volume 10 Number 7 July 2008 pp. 68
- Page 121 and 122: 682 RAS Signaling in Colorectal Car
- Page 123 and 124: 684 RAS Signaling in Colorectal Car
- Page 125 and 126: 686 RAS Signaling in Colorectal Car
- Page 127: Table W2. Detailed Somatic Events o
- Page 131 and 132: Identification of RCC2 as a prognos
- Page 133 and 134: INTRODUCTIONMicrosatellite instabil
- Page 135 and 136: unselected series of primary tumors
- Page 137 and 138: specificity, i.e. that they only am
- Page 139 and 140: On the assumption that DNA repair a
- Page 141 and 142: In order to ensure that gene mutati
- Page 143 and 144: Figure 2. Mutation frequency differ
- Page 145 and 146: and TAF1B (0.50), ACVR2A and ASTE1
- Page 147 and 148: Multivariate analysesA multivariate
- Page 149 and 150: When comparing our findings of muta
- Page 151 and 152: The test series included a low numb
- Page 153: entering M-phase remains to be seen
- Page 157 and 158: 34. Martineau-Thuillier S, Andreass
- Page 159: AppendicesAppendix I:List of abbrev
- Page 163 and 164: Critical Reviews TM in Oncogenesis,
- Page 165 and 166: TARGET GENES OF MSI COLORECTAL CANC
- Page 167 and 168: TARGET GENES OF MSI COLORECTAL CANC
- Page 169 and 170: TARGET GENES OF MSI COLORECTAL CANC
- Page 171 and 172: TARGET GENES OF MSI COLORECTAL CANC
- Page 173 and 174: TARGET GENES OF MSI COLORECTAL CANC
- Page 175 and 176: TARGET GENES OF MSI COLORECTAL CANC
- Page 177 and 178: TARGET GENES OF MSI COLORECTAL CANC
- Page 179 and 180: TARGET GENES OF MSI COLORECTAL CANC
- Page 181 and 182: TARGET GENES OF MSI COLORECTAL CANC
- Page 183 and 184: TARGET GENES OF MSI COLORECTAL CANC
- Page 185 and 186: TARGET GENES OF MSI COLORECTAL CANC
- Page 187 and 188: TARGET GENES OF MSI COLORECTAL CANC
- Page 189 and 190: TARGET GENES OF MSI COLORECTAL CANC
- Page 191: TARGET GENES OF MSI COLORECTAL CANC